Search

Your search keyword '"Cencioni, G"' showing total 3 results
Start Over Author "Cencioni, G" Language english
3 results on '"Cencioni, G"'

1. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir

Author

Monini, P, Sgadari, C, Grosso, M, Bellino, S, Di Biagio, A, Toschi, E, Bacigalupo, I, Sabbatucci, M, Cencioni, G, Salvi, E, Leone, P, Ensoli, B, Barillari, G, Moracci, G, Carratelli, L, Gatti, G, Brambilla, L, Brambati, M, Ferrucci, S, De Pita, O, Pilla, M, Di Carlo, A, Giuliani, M, Cottoni, F, Cuccuru, M, Calvieri, S, Clerico, R, Potenza, C, Tirelli, U, Simonelli, C, Martellotta, F, Strumia, R, Borghi, A, Del Giacco, S, Moi, L, Piludu, G, Sirianni, M, Campagna, M, Sarmati, L, Andreoni, M, Bianchini, G, Sheldon, J, Milzer, J, and Schulz, T

Subjects
Aged, Aged, 80 and over, Antibodies, Viral, Antineoplastic Agents, Biomarkers, Tumor, HIV Protease Inhibitors, HIV Seronegativity, Herpesvirus 8, Human, Humans, Indinavir, Middle Aged, Sarcoma, Kaposi, Treatment Outcome, Settore MED/09 - Medicina Interna, Settore MED/17 - Malattie Infettive, Immunology, Kaposi, Biology, Virus, Antibodies, Acquired immunodeficiency syndrome (AIDS), medicine, 80 and over, Immunology and Allergy, HIV Protease Inhibitor, Protease inhibitor (pharmacology), Viral, Herpesvirus 8, Kaposi's sarcoma, Tumor, virus diseases, Sarcoma, Settore MED/07 - Microbiologia e Microbiologia Clinica, medicine.disease, biology.organism_classification, Infectious Diseases, Lentivirus, Biomarkers, medicine.drug, Human
Abstract

HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.

Published
2009

2. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir.

Author

Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, and Ensoli B

Subjects
Aged, Aged, 80 and over, Antibodies, Viral blood, Antineoplastic Agents blood, Biomarkers, Tumor blood, HIV Protease Inhibitors blood, HIV Seronegativity, Herpesvirus 8, Human immunology, Humans, Indinavir blood, Middle Aged, Sarcoma, Kaposi blood, Treatment Outcome, Antineoplastic Agents therapeutic use, HIV Protease Inhibitors therapeutic use, Indinavir therapeutic use, Sarcoma, Kaposi drug therapy
Abstract

HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.

Published
2009
Full Text
View/download PDF

3. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.

Author

Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Cusi MG, Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, Lemonnier FA, Jackson AM, and Kosmatopoulos K

Subjects
Animals, Cell Line, Tumor, Humans, Mice, Mice, Transgenic, Models, Genetic, Neoplasm Transplantation, Peptides chemistry, Receptor, ErbB-2 metabolism, Thymoma metabolism, Cancer Vaccines chemistry, Epitopes chemistry, Neoplasms therapy, Receptor, ErbB-2 chemistry, T-Lymphocytes, Cytotoxic metabolism, Vaccines, DNA chemistry
Abstract

A cDNA vaccine (pVax1/pet-neu) was designed to encode 12 different Her-2/ErbB-2-derived, HLA-A*0201-restricted dominant and high-affinity heteroclitic cryptic epitopes. Vaccination with pVax1/pet-neu triggered multiple and ErbB-2-specific CTL responses in HLA-A*0201 transgenic HHD mice and in HLA-A*0201 healthy donors in vitro. Human and murine CTL specific for each one of the 12 ErbB-2 peptides recognized in vitro both human and murine tumor cells overexpressing endogenous ErbB-2. Furthermore, vaccination of HHD mice with pVax1/pet-neu significantly delayed the in vivo growth of challenged ErbB-2-expressing tumor (EL4/HHD/neu murine thymoma) more actively when compared with vaccination with the empty vector (pVax1) or vehicle alone. These data indicate that the pVax1/pet-neu cDNA vaccine coding for a poly-ErbB-2 epitope is able to generate simultaneous ErbB-2-specific antitumor responses against dominant and cryptic multiple epitopes.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results